tiprankstipranks
Jacobson Pharma Sees Strong Growth in 2024 Interim Results
Company Announcements

Jacobson Pharma Sees Strong Growth in 2024 Interim Results

Jacobson Pharma Corporation Limited (HK:2633) has released an update.

Don't Miss our Black Friday Offers:

Jacobson Pharma Corporation Limited reported a robust financial performance for the six months ending September 2024, with a 13.3% increase in revenue to HK$810.0 million and a 44.2% surge in profit from continuing operations to HK$140.3 million. The company also declared a 40% higher interim dividend, reflecting strong growth compared to the same period in 2023. These results highlight the company’s resilient business model and its promising outlook for investors.

For further insights into HK:2633 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App